The FDA will now allow food labels to claim products have “no artificial colors” as long as they avoid petroleum-based dyes.

Among children younger than 2, the preventive effects of nirsevimab against RSV were maintained for up to 12 months after administration.

Study data presented at ACTRIMS 2026 suggests clinical MS onset may precede laboratory-confirmed primary EBV infection in some patients.

COVID-19 infection prevention measures in NICUs significantly reduced viral HAIs but not bacterial or fungal rates.

The table below is a review of notable updates that occurred in January 2026 for investigational products in development (not an inclusive list). Click on the status to view our full coverage.

For HPV testing for detection of cervical intraepithelial neoplasia grade 2/3 or worse, minipad-collected menstrual blood shows comparable diagnostic accuracy.

Another major medical group says most gender-related surgeries for minors in the U.S. should be postponed until adulthood.

Implementing weekly, high-risk rounds in the pediatric intensive care unit reduces the risk for hospital-acquired conditions.

Structured public health referral programs like CureTB help sustain treatment continuity for patients with tuberculosis relocating internationally.

A comprehensive review found no evidence to support the changes made by the CDC to the recommendations for hepatitis B vaccination in children.

A phase 3 trial finds pritelivir significantly improves cure rates for immunocompromised individuals with refractory HSV infections.

Young adults with childhood-onset complex chronic conditions have longer acute care medical hospitalizations, higher costs, and higher readmission rates.